Bukwang Pharmaceutical saw the highest growth of 0.99% in patent filings in April and 0.24% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Bukwang Pharmaceutical‘s patent filings and grants. Buy the databook here.
Bukwang Pharmaceutical has been focused on protecting inventions in Australia(AU) with one publication in Q2 2024
The Australia(AU) Patent Office dominates the patent grants with nearly 20% of grants. The Australia(AU), Canada(CA), European Patent Office(EPO), and Spain(ES) patent Office are among the top ten patent offices where Bukwang Pharmaceutical is filings its patents. Among the top granted patent authorities, Bukwang Pharmaceutical has 20% of its grants in Australia(AU), 20% in Canada(CA) and 20% in Spain(ES).
Nestle and IntraBio could be the strongest competitors for Bukwang Pharmaceutical
Patents related to rare diseases lead Bukwang Pharmaceutical's portfolio
Bukwang Pharmaceutical has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Parkinson's disease related patents lead Bukwang Pharmaceutical portfolio followed by movement disorders, and dyskinesia
Bukwang Pharmaceutical has highest number of patents in parkinson's disease followed by movement disorders, dyskinesia, canavan disease, and mobiles, hand-helds, pdas, smartphones.
For comprehensive analysis of Bukwang Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.